Merck Healthcare

11 PBAC submissions on file, active 2020–2024. 73% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Avelumab
  Oncology · Recommended with restriction · 2022$57M
• Cladribine
  Neurology · Not recommended · 2023other sponsor
• Cetuximab
  Oncology · Recommended · 2024—
• Follitropin alfa
  Women's health · Not recommended · 2021other sponsor
• Follitropin alfa with lutropin alfa
  Women's health · Recommended with restriction · 2024—
• Somatropin
  Endocrinology · Recommended with restriction · 2023—
• Tepotinib
  Oncology · Recommended with restriction · 2021—

Therapy area mix

Activity by year

2020 (1) · 2021 (5) · 2022 (1) · 2023 (2) · 2024 (2)

Rejection patterns

Across 3 Not recommended decisions on file.

• 1×Clinical claim of non-inferior comparative efficacy and safety over four years not adequately justified
• 1×surrogate outcomes (treatment switch
• 1×discontinuation) poorly correlated with relapse
• 1×non-randomised data with significant baseline imbalances
• 1×propensity score matching did not fully address confounding